Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label weekly. Show all posts
Showing posts with label weekly. Show all posts
Saturday, July 07, 2012

paywalled- Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis

›
Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis Abstract Background ...
Tuesday, January 03, 2012

Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer

›
  Objectives:  The purpose of this study was to assess the response rate, toxicity, progression-free survival, and overall survival in a s...
Saturday, May 21, 2011

Markman commentary: Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown

›
Gynecologic Oncology Article in Press doi:10.1016/j.ygyno.2011.04.020  |  How to Cite or Link Using DOI C...

abstract: Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer:

›
CONCLUSIONS: Combination chemotherapy in platinum-resistant ROC was more toxic than weekly paclitaxel and did not significantly prolong PF...
Wednesday, February 16, 2011

Randomized Phase III Clinical Trial Evaluating Weekly Cisplatin for Advanced Epithelial Ovarian Cancer — J. Natl. Cancer Inst.

›
Thus, increasing dose intensity of cisplatin does not improve PFS or OS compared with standard chemotherapy.
Friday, January 14, 2011

Randomized Phase III Clinical Trial Evaluating Weekly Cisplatin for Advanced Epithelial Ovarian Cancer

›
"Thus, increasing dose intensity of cisplatin does not improve PFS or OS compared with standard chemotherapy."
Friday, August 06, 2010

Weekly paclitaxel in the treatment of recurrent ovarian cancer - abstract

›
Abstract: Weekly paclitaxel is a highly active and well tolerated regimen that is increasingly being adopted for the treatment of relap...
Tuesday, June 15, 2010

Efficacy of lower dose of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer resistant to platinum-based therapy

›
Conclusions: Lower dose of weekly topotecan was well tolerated in patients with platinum-resistant ovarian or peritoneal cancer at fir...
Saturday, January 23, 2010

Jan 23, 2009: Commentary (1 of 2): Dose-dense paclitaxel for advanced ovarian cancer : The Lancet

›
Note : may require registration (free):